Point72 Asia Singapore Pte. Ltd. Buys Shares of 11,404 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Point72 Asia Singapore Pte. Ltd. purchased a new position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 2nd quarter, Holdings Channel reports. The firm purchased 11,404 shares of the company’s stock, valued at approximately $234,000.

Other institutional investors also recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Syndax Pharmaceuticals in the 2nd quarter worth about $33,000. CANADA LIFE ASSURANCE Co raised its holdings in shares of Syndax Pharmaceuticals by 28.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 7,182 shares of the company’s stock valued at $171,000 after purchasing an additional 1,587 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Syndax Pharmaceuticals by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock valued at $187,000 after purchasing an additional 1,312 shares during the period. American Century Companies Inc. bought a new stake in Syndax Pharmaceuticals in the 2nd quarter worth approximately $201,000. Finally, EntryPoint Capital LLC raised its stake in Syndax Pharmaceuticals by 487.1% during the 1st quarter. EntryPoint Capital LLC now owns 8,636 shares of the company’s stock valued at $206,000 after buying an additional 7,165 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on SNDX shares. JPMorgan Chase & Co. cut their price objective on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Citigroup increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Stifel Nicolaus upped their target price on shares of Syndax Pharmaceuticals from $40.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 26th. HC Wainwright increased their price target on shares of Syndax Pharmaceuticals from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, Scotiabank downgraded shares of Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.33.

Syndax Pharmaceuticals Stock Up 0.8 %

NASDAQ SNDX opened at $18.16 on Friday. The business has a 50-day moving average price of $20.24 and a 200-day moving average price of $21.02. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -5.64 and a beta of 0.91. Syndax Pharmaceuticals, Inc. has a twelve month low of $11.22 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.11. The company had revenue of $3.50 million for the quarter. Syndax Pharmaceuticals’s quarterly revenue was up 3499999990.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.64) earnings per share. Research analysts expect that Syndax Pharmaceuticals, Inc. will post -3.66 EPS for the current fiscal year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).